Khoury Joseph D
a Division of Pathology and Laboratory Medicine, Department of Hematopathology , the University of Texas M.D. Anderson Cancer Center , Houston , TX , USA.
Scand J Clin Lab Invest Suppl. 2016;245:S22-5. doi: 10.1080/00365513.2016.1206444. Epub 2016 Jul 19.
The scope of companion diagnostics in cancer has undergone significant shifts in the past few years, with increased development of targeted therapies and novel testing platforms. This has provided new opportunities to effect unprecedented paradigm shifts in the application of personalized medicine principles for patients with cancer. These shifts involve assay platforms, analytes, regulations, and therapeutic approaches. As opportunities involving each of these facets of companion diagnostics expand, close collaborations between key stakeholders should be enhanced to ensure optimal performance characteristics and patient outcomes.
在过去几年中，癌症伴随诊断的范围发生了重大变化，靶向治疗和新型检测平台的开发不断增加。这为在癌症患者个性化医疗原则的应用中实现前所未有的范式转变提供了新机会。这些转变涉及检测平台、分析物、法规和治疗方法。随着伴随诊断各个方面的机会不断扩大，关键利益相关者之间应加强密切合作，以确保最佳的性能特征和患者治疗效果。
